Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $55.00 price target on DBV Technologies S.A (NASDAQ: DBVT).

The analyst commented, "DBVT’s BLA submission marks an important milestone for the company and given management’s implementation of recent FDA input regarding the organization, mapping, and formatting of existing data sets for the CMC and biostatistical elements of the BLA – we think an acceptance is likely by the end of November. We think that acceptance could move shares meaningfully higher as investors gain more confidence in Viaskin Peanut’s approval and get a line of sight to a potential launch. To that end, if the Agency grants Priority Review, we would expect an approval by the end of May. A standard review would place the PDUFA by the end of September. We currently model a 3Q27 launch in the 4-7–year-old group, and we also expect a BLA submission for the 1-3–year-old group this year. We continue to view approval of Viaskin Peanut in both age groups as highly likely (90% POS) and model ~$3B in peak U.S. sales for Viaskin Peanut."

For an analyst ratings summary and ratings history on DBV Technologies S.A click here. For more ratings news on DBV Technologies S.A click here.

Shares of DBV Technologies S.A closed at $11.55 yesterday.